Wednesday 19th January 2022 |
Text too small? |
At a Special Meeting held online today, Wednesday 19 January 2022, Rua Bioscience shareholders voted in favour of Rua acquiring Zalm Therapeutics. Shareholders were asked to vote on a resolution being:
That the issue of:
• 8,140,000 new ordinary shares (Initial Shares); and
• 16,280,000 equity securities having the right to convert into ordinary shares on achievement of the milestones described in the explanatory notes (Performance Shares) to the shareholders of Zalm Therapeutics Limited (which may together eventually result in those subscribers holding 28,735,632 fully paid ordinary shares in the Company) be approved for all purposes, including for the purposes of NZX Listing Rule 4.2.1(a).
As required by NZX Listing Rule 6.1, all voting was conducted by a poll. The resolution was passed by the required majority, and the result of the voting is attached.
Please see the link below for details
Source: Rua Bioscience Limited
No comments yet
Fonterra appoints permanent COO
Manawa Energy FY24 Annual Results & Webcast Details
Seeka Provides the Results of Meeting - ASM
April 19th Morning Report
PGW Guidance Update
CNU - Commerce Commission releases draft expenditure decision
Spark announces departure of Product Director
TGG - T&G appoints new Director
April 18th Morning Report
SKC - APPOINTMENT OF CHIEF EXECUTIVE OFFICER